http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
약제 내성 만성 B형간염 환자에서 테노포비어를 포함한 구원치료의 효과
박재우 ( Park jae woo ),천갑진 ( Gab Jin Cheon ),최강혁 ( Kang Hyug Choi ),이한민 ( Han Min Lee ),전백규 ( Baek Gyu Jun ),김홍수 ( Hong Soo Kim ),김상균 ( Sang Gyune Kim ),김영석 ( Young Seok Kim ),김부성 ( Boo Sung Kim ),정승원 ( 대한소화기학회 2015 대한소화기학회지 Vol.65 No.1
Background/Aims: Tenofovir disoproxil fumarate (TDF) plays a pivotal role in the management of drug-resistant chronic hepatitis B. However, it remains unclear whether TDF-nucleoside analogue combination therapy provides better outcomes than TDF monotherapy. This study aimed to compare the efficacy of TDF monotherapy with that of TDF-nucleoside analogue combination therapy in patients with drug-resistant chronic hepatitis B. Methods: This retrospective cohort study included 76 patients receiving TDF-based rescue therapy for more than 12 months. Suboptimal response was defined as serum HBV-DNA level of >60 IU/mL during prior rescue therapy. Multi-drug resistance was defined as the presence of two or more drug resistance-related mutations confirmed by mutation detection assay. The relationship between baseline characteristics and virologic response (HBV DNA <20 IU/mL) at 12 months were evaluated using logistic regression analysis. Results: Fifty-five patients (72.4%) were suboptimal responders to prior rescue therapy, and 26 (34.2%) had multi-drug resistance. Forty-two patients (55.3%) received combination therapy with nucleoside analogues. Virologic response at 12 months was not significantly different between the TDF monotherapy group and TDF-nucleoside analogue combination therapy group (p=0.098). The serum HBV DNA level was reduced to .4.49±1.67 log10 IU/mL in the TDF monotherapy group and to .3.97±1.69 log10 IU/mL in the TDF-nucleoside analogue combination therapy group at 12 months (p=0.18). In multivariate analysis, female sex (p=0.032), low baseline HBV-DNA level (p=0.013), and TDF monotherapy (p=0.046) were predictive factors for virologic response at 12 months. Conclusions: TDF monotherapy showed similar efficacy to that of TDF-nucleoside analogue combination therapy in patients with drug-resistant chronic hepatitis B.
캐슬만병에서 기원하여 무증상 복강 내 종양으로 발현된 여포성 수상돌기 세포육종
황순오 ( Soon Oh Hwang ),이태훈 ( Ae Hoon Lee ),배상호 ( Sang Ho Bae ),조현득 ( Hyun Deuk Cho ),최강혁 ( Kang Hyug Choi ),박상흠 ( Sang Heum Park ),김창호 ( Chang Ho Kim ),김선주 ( Sun Joo Kim ) 대한소화기학회 2013 대한소화기학회지 Vol.62 No.2
Follicular dendritic cell (FDC) sarcoma is an extremely rare malignant neoplasm arising from FDCs. The exact origin of FDCs remains unclear; both a hematopoietic lineage origin and a stromal cell derivation have been proposed. Proliferation of FDCs can lead to benign reactive lesions or generate neoplastic conditions. The lesions are most commonly found in lymph nodes and usually involve the head and neck area. Castleman`s disease is a rare non-neoplasitic lymphoproliferative disorder. Rare cases of hyaline-vascular Castleman`s disease have been associated with FDC sarcoma, but a clonal relationship has not been convincingly demonstrated. A pathway toward tumor evolution, beginning with hyperplasia and dysplasia of FDCs, has been proposed. Despite this known association between Castleman`s disease and FDC sarcoma, there have only been few reported cases of sarcoma arising as a complication of pre-existing Castleman`s disease, especially in abdominal lesions. We describe here a 51-year-old female with an FDC sarcoma arising from unicentric, hyaline-vascular type Castleman s disease in an intra-abdominal mass. Pathologically, the lesion showed a series of changes during the process of transformation from Castleman`s disease to FDC sarcoma. (Korean J Gastroenterol 2013; 62:131-134)